RIPK2 and lymphoma: After analysing the immunohistochemical results, RIPK2 expression was only medium–high in Endometrial cancer (8/12 patients), Lymphoma (6/11 patients) and Prostate cancer (6/12 patients), and the proportion of medium–high expression of RIPK2 in endometrial cancer, lymphoma and prostate cancer tissues was higher than that of low or negative expression (Fig. 2).